|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3850 AUD | 0.00% |
|
+1.32% | -40.77% |
| 30/07 | Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy | MT |
| 21/07 | Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter | MT |
| Market Cap | 115M 81.4M 70.54M 66.04M 60.26M 113M 7.76B 774M 303M 3.89B 306M 299M 12.96B | P/E 2026 * |
-6.31x | P/E 2027 * | -4.53x |
|---|---|---|---|---|---|
| Enterprise Value | 121M 85.1M 73.74M 69.04M 62.99M 119M 8.12B 809M 317M 4.06B 320M 313M 13.55B | EV / Sales 2026 * |
15.5x | EV / Sales 2027 * | 11.2x |
| Free-Float |
62.73% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 week | +1.32% | ||
| Current month | +4.05% | ||
| 3 months | -23.00% | ||
| 6 months | -36.89% | ||
| Current year | -40.77% |
| 1 week | 0.37 |  | 0.38 |
| 1 month | 0.35 | | 0.39 |
| Current year | 0.35 | | 0.73 |
| 1 year | 0.35 | | 0.73 |
| 3 years | 0.28 | | 0.74 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 28/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 01/10/2012 |
James Graham
BRD | Director/Board Member | - | 01/05/2012 |
| Director/Board Member | - | 01/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24/2/26 | Expiration | Chief Executive Officer | 2,250,000 | 0.7781% | ||
| 14/10/25 | Expiration | Chief Executive Officer | 745,962 | 0.3217% | ||
| 21/11/24 | Buy | Director | 1,000,000 | 0.4313% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +1.32% | +2.67% | -46.90% | 81.46M | |
| -1.37% | +8.90% | +91.28% | +130.00% | 1,098B | |
| -0.77% | +1.91% | +49.46% | +49.44% | 631B | |
| +0.85% | +2.58% | +25.90% | +64.34% | 438B | |
| -1.13% | +3.62% | +49.72% | +38.22% | 368B | |
| -0.74% | +1.09% | +33.81% | +38.95% | 298B | |
| -1.22% | +2.99% | +8.44% | +6.11% | 251B | |
| -0.70% | +6.23% | +45.32% | +57.82% | 226B | |
| +0.34% | +1.62% | -4.91% | -50.77% | 209B | |
| +2.04% | +0.38% | +12.70% | +69.71% | 165B | |
| Average | -0.09% | +1,491.53% | +31.44% | +35.69% | 368.44B | |
| Weighted average by Cap. | -0.51% | +1,331.47% | +50.10% | +66.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.78M 5.49M 4.76M 4.46M 4.07M 7.65M 524M 52.24M 20.47M 262M 20.62M 20.17M 875M | 12.5M 8.82M 7.65M 7.16M 6.53M 12.29M 841M 83.92M 32.88M 421M 33.12M 32.4M 1.41B |
| Net income | -18.29M -12.91M -11.19M -10.48M -9.56M -17.99M -1.23B -123M -48.13M -617M -48.49M -47.43M -2.06B | -25.1M -17.72M -15.36M -14.38M -13.12M -24.68M -1.69B -169M -66.04M -846M -66.53M -65.08M -2.82B |
| Net Debt | 5.24M 3.7M 3.2M 3M 2.74M 5.15M 353M 35.16M 13.78M 176M 13.88M 13.58M 589M | 24.96M 17.62M 15.27M 14.3M 13.05M 24.55M 1.68B 168M 65.69M 841M 66.18M 64.73M 2.81B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/08/26 | $0.3850 | 0.00% | 62,051 |
| 10/08/26 | $0.3850 | +2.67% | 47,133 |
| 07/08/26 | $0.3750 | -1.32% | 54,492 |
| 06/08/26 | $0.3800 | +1.33% | 45,217 |
| 05/08/26 | $0.3750 | 0.00% | 7,916 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
